Clinical Trial Title
A phase Ill randomized trial investigating bortezomib (NSC #681239; IND #58443) on a modified augmented BFM (ABFM) backbone in newly diagnosed T-lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LLy).Clinical Trial Protocol Description:
To compare event free survival in patients with newly diagnosed T-ALL and T-lymphoblastic lymphoma who are randomized to a modified ABFM (chemotherapy) backbone versus bortezomib plus the modified ABFM backbone.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are between 1 and 31 years of age.
- Have newly diagnosed T-lymphoblastic leukemia (T-ALL) or T-lymphoblastic lymphoma (T-LLy) stages II-IV.
This is a partial list of eligibility requirements.
Study Details
Clinical Trial Investigator
Mary Lou Schmidt, MD
Contact Information
RUSH MD Anderson Cancer Center Clinical Trials Office